Results

Total Results: 2,080 records

Showing results for "drug".

101. FRN 35 - Preventive Pharmacological Treatments for Migraine in Adults: Future Research Needs (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/migraine-future_research.pdf
     April 01, 2013 - Are drug side effects lessened when two drugs are used at lower dosages instead of one drug at a higher … , patient education, drug surveillance, or interactive drug monitoring) influence results? … , patient education, drug surveillance, or interactive drug monitoring) influence results? … Are drug side effects lessened when two drugs are used at lower dosages instead of one drug at a higher … What is the appropriate timing to evaluate treatment success or failure for each drug/class of drug for

102. Evidence Report on the (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/osteoarthritis-pain_research-protocol.pdf
     August 05, 2010 - that standard dosing as labeled or alternative dosage strategies, such as intermittent dosing and drug … Oral drugs (trade names provided only for drugs under patent) Drug (any trade name): acetaminophen … systemic lupus erythematosus; rheumatoid arthritis; stable angina, chronic; unstable angina Drug … impairment: reduce dose by 50%; elderly patients weighing < 50 kg: initiate at lowest dose Drug … /day Renal impairment and elderly: initiate with lowest dose possible, then monitor closely Drug

103. Comparative Effectiveness of Oral Hypoglycemics for Reducing Diabetic Nephropathy | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/diabetes-oral-medicines-nephropathy/research
     January 01, 2005 - Pharmacoepidemiol Drug Saf 2013 Feb 24 [Epub ahead of print]. PMID: 23436488.

104. Effective Health Care (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND_0264_01-14-2008.pdf
     January 01, 2008 - For children with juvenile idiopathic arthritis, do drug therapies differ in their ability to reduce … For children with juvenile idiopathic arthritis, do drug therapies differ in their ability to Juvenile … For children with juvenile idiopathic arthritis, do drug therapies differ in harms, tolerability, adherence … What are the comparative benefits and harms of drug therapies for juvenile idiopathic arthritis in

105. Obesity (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/obesity-horizon-scan-high-impact-1406.pdf
     June 01, 2014 - The drug has been classified by the U.S. … Drug Enforcement Administration as a Schedule IV drug; it became available for prescribing in June … Drug Enforcement Administration (DEA) as a Schedule IV drug (i.e., with a low potential for abuse and … The drug also decreases glucose levels. … Food and Drug Administration (FDA)).

106. Evidence-based Practice Center Systematic Review Protocol: Therapies for Clinically Localized Prostate Cancer (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/prostate-cancer-therapies-protocol_amended110619.pdf
     November 02, 2019 - [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer … [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer … [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer … [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer … [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer

107. Infectious Disease Including HIV/AIDS #09 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/infectious-disease-horizon-scan-high-impact-1506.pdf
     December 01, 2015 - Two third- party payers consider Sovaldi a preferred drug; eight consider Harvoni a preferred drug. … Daklinza is an investigational HCV NS5A inhibitor.15 The drug purportedly has a low drug-drug interaction … Gilead gets U.S. approval to sell new hepatitis C drug: drug is seen building on the highly successful … Sovaldi and reigniting debate about drug prices. … Nat Rev Drug Discov. 2013 Jun;12(6):409-11.

108. A Multicenter, Observational Cohort Study to Assess the Cardiovascular Risks of Medications Prescribed for Attention Deficit Hyperactivity Disorder | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/adhd-medicines-risks/abstract
     January 01, 2005 - Doubts about the safety of ADHD drug use were raised recently by a U.S. … Food and Drug Administration review of its Adverse Event Reporting System (AERS) for cases of sudden … manuscript will describe the group’s experience in pulling data from multiple sites and sources for drug … [Epub ahead of print] FDA Drug Safety Communication: Safety review update of medications used to treat

109. Dietary-Supplements Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/dietary-supplements_executive.pdf
     April 01, 2012 - patients’ supplement use.15,16 While a substantial amount of research and data is available describing drug–drug … Clinical cardiovascular effectiveness/efficacy of cardiovascular drug(s) plus supplement versus drug … Intermediate cardiovascular efficacy outcomes of cardiovascular drug(s) plus supplement versus drug … Pharmacokinetic outcomes with cardiovascular drug(s) plus supplement versus drug(s) plus placebo, no … involved in drug metabolism.

110. Nonopioid Pharmacologic Treatments for Chronic Pain: Evidence Summary (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/nonopioid-chronic-pain-summary.pdf
     April 01, 2020 - Harms results are organized by drug class. … ); NS = nonsteroidal anti-inflammatory drug; nsNSAID = nonselective nonsteroidal anti-inflammatory drug … Administration warnings, drug information texts). … Food and Drug Administration website. … Food and Drug Administration website.

111. Evaluating the Effects of Drug-Eluting and Bare Metal Stents in Patient Subgroups and Comparing Diagnostic Tools in Predicting Outcomes Following Stenting Procedures | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/coronary-stents-effects/abstract
     December 15, 2009 - Evaluating the Effects of Drug-Eluting and Bare Metal Stents in Patient Subgroups and Comparing Diagnostic … Safety and efficacy of drug-eluting stents in older persons with chronic kidney disease: a report from

112. Obesity (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/obesity-horizon-scan-high-impact-1312.pdf
     December 01, 2013 - Drug Enforcement Administration (DEA) designated lorcaserin as a Schedule IV drug, which removed the … The drug has been classified by DEA as a Schedule IV drug; it became available for prescribing in June … Drug Enforcement Administration (DEA) as a Schedule IV drug (i.e., with a low potential for abuse … It was the first drug approved to treat obesity since 1999.69,71,73 However, FDA referred the drug … FDA approves Qsymia, a weight-loss drug. [internet].

113. Pharmacotherapy for Adults with Alcohol-Use Disorders in Outpatient Settings (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/alcohol-misuse-drug-therapy-surveillance.pdf
     September 01, 2017 - 16 97 Anton61 2011 naltrexone, acamprosate, gabapentin Medium 150 Largest for drug only 3 drug … Medium 150 Largest for drug 29 88 Naranjo69 1995 citalopram High 150 Largest for drug 64 149 Kranzler70 … Drug and alcohol dependence. 2013;133(2):440-446. 21. … Drug and alcohol dependence. 2013;133(2):754-758. 26. … The American journal of drug and alcohol abuse. 2017;43(3):324-331. 31.

114. Treatment for Restless Legs Syndrome: Future Research Needs (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/restless-legs-future_research.pdf
     February 01, 2013 - Intervention RLS treatment, including both drug therapies and nondrug therapies. … RLS treatment, including both drug therapies and nondrug therapies. … (Both drug and nondrug treatment options could be considered.) Treatment for RLS. … With RLS Drug: SPM 962 NCT00656110 Neuroma Injections to Treat Restless Legs Syndrome - RCT Drug … Drug Interaction Study With Gabapentin Enacarbil and Morphine Drug: morphine; Placebo NCT01516372

115. Migraine-Prevention Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/migraine-prevention_executive.pdf
     June 01, 2013 - , patient education, drug surveillance, or interactive drug monitoring) influence results? … , patient education, drug surveillance, or interactive drug monitoring) improve safety of the treatments … , patient education, drug surveillance, or interactive drug monitoring) influence results? … care, patient education, drug surveillance, or interactive drug monitoring) improve safety of the … Adverse drug reactions and off-label drug use in paediatric outpatients.

116. Comparative Effectiveness and Safety: Emerging Methods - Part I | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/safety-emerging-methods/executive
     September 25, 2007 - Designed Delays Versus Rigorous Pragmatic Trials: Lower Carat Gold Standards Can Produce Relevant Drug … Developing Indicators of Inpatient Adverse Drug Events Through Nonlinear Analysis Using Administrative … Developing Indicators of Inpatient Adverse Drug Events Through Non-Linear Analysis Using Administrative … Evaluation and Overview of the National Electronic Injury Surveillance System-Cooperative Adverse Drug … Evaluation and overview of the National Electronic Injury Surveillance System-Cooperative Adverse Drug

117. PULMONARY with "Discussions" in Exec Summary (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pulmonary-horizon-scan-high-impact-1306.pdf
     June 01, 2013 - The drug is administered orally, at a dosage of 250 mg, once daily. … Available: http://www.vrtx.com/current-projects/drug- candidates/vx-770.html. 3. … Food and Drug Administration (FDA); 2012 Jan 31 [accessed 2012 Feb 22]. [2 p]. … Aetna non-Medicare prescription drug plan. Subject: cystic fibrosis. [internet]. … Food and Drug Administration (FDA) [accessed 2012 Jun 28]. [2 p].

118. Obesity (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/obesity-horizon-scan-high-impact-1306.pdf
     July 01, 2013 - The drug has been classified by the U.S. … Drug Enforcement Administration as a Schedule IV drug; it became available for prescribing in June … Health care delivery infrastructure and patient management: As an oral drug, this drug would not significantly … Drug Enforcement Administration (DEA) as a Schedule IV drug (i.e., with a low potential for abuse … FDA approves Qsymia, a weight-loss drug. [internet].

119. S5 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/s5.pdf
     October 01, 2007 - Lohr, PhD Background: Interest in new methods for comparative effective- ness, drug and patient safety … structure both interventional and database-oriented studies, particu- larly those concerned with adverse drug … Key Words: comparative effectiveness, drug safety, health care, methods, patient safety, pharmaceuticals … ), trends in evidence-based practice and effective health care, together with Medicare Prescription Drug … L. 108–173), have converged to spotlight issues of drug effec- tiveness and safety.

120. Infectious Disease Including HIV/AIDS #09 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/infectious-disease-horizon-scan-high-impact-1512.pdf
     January 28, 2016 - Five third-party payers consider Sovaldi a preferred drug; nine consider Harvoni a preferred drug. … Daklinza purportedly has a low drug-drug interaction profile, which could support its use in patients … Guideline #CG-DRUG-07. [internet]. … Hepatitis virus drug therapy. Drug policy #05.01.50. [internet]. … Specialty drug list. [internet].